Slide 1
Image is not available

Our mission is to develop a radically new approach for the treatment of severe, chronic autoimmune diseases.


IMCYSE Denis Bedoret

Denis Bedoret, Ph.D.

Chief Executive Officer

Denis Bedoret joined Imcyse in September 2020 as Chief Executive Officer. Prior to joining Imcyse, Denis was Chief Executive Officer at MaSTherCell SA, Belgium and President of MaSTherCell Global Inc., U.S. for four years. Under his leadership, the Company expanded significantly growing from 60 to 260 employees and positioning as a leader in the field of CDMO’s dedicated to Cell and Gene therapies products. Catalent Pharma Solutions, Inc. acquired MaSTherCell and Denis managed the transition period. Prior to his position at MaSTherCell, Denis held the position of Chief Operations Officer at Quality Assistance S.A. a leading European analytical CRO where he was also a member of the Board of Directors. Before that, Denis served as engagement manager at McKinsey & Company, focusing on life science projects. Through these experiences, Denis has gained strong expertise in the global development of innovative human medical products with a focus on biologicals as well as in corporate strategy development and implementation. Denis holds a degree in Veterinary Medicine, a Ph.D. in Life Sciences from the University of Liège and a postdoc in Immunology from Harvard Medical School.

IMCYSE Denis Bedoret

Anneleen Boyden, PMP

Director PMO

Anneleen Boyden joined Imcyse in October 2021 as Director PMO (Project Management Office). She has over 21 years of experience in the pharma/biotech sector in pre-clinical, clinical & PMO and has drug development experience in a wide range of Therapeutic Areas (CNS, Immunology, Infectious Diseases, Internal Medicine and Oncology). Prior to joining Imcyse, Anneleen was Program Leader Drug Development (as independent consultant) at Argenx where she supported the company in its significant growth (from about 100 to 500 employees/consultants), in leading cross-functional teams E2E and in building up a Project Management department. Prior to that she held different positions at/collaborated with Janssen, Innogenetics, UCB and GSK. Anneleen is a certified PMI Project Management Professional (PMP) and holds a degree in career coaching from HRD Academy, as well as a Professional Bachelor in Pharmaceutical and Biological Technologies from the Katholieke Hogeschool Leuven.

IMCYSE Vincent Carlier

Vincent Carlier, Ph.D

R&D Director Immunology

Vincent Carlier has been with Imcyse since its inception. He has been part of the Company’s management team since its foundation dedicated to the development of Imcyse’s technology. Vincent is in charge of R&D management, preclinical research and development, immunology and cellular assays, transversal research and read-outs. Vincent holds a Ph.D. in Biomedical Sciences from the Catholic University of Leuven (KUL), and worked for different departments within KUL as a researcher: the Collen Research Foundation Center for Molecular and Vascular Biology and Life Science Research Partners (LSRP) on the development of the ImotopeTM technology.

Imcyse Geoffrey Gloire

Geoffrey Gloire, Ph.D

IP Director

Geoffrey Gloire joined Imcyse in 2016 as IP Director. He is in charge of the protection and valorisation of Imcyse’s intellectual property. Prior to joining the Imcyse team, Geoffrey was a Patent Advisor in Life Sciences at the University of Liège Technology Transfer Office from 2011 until June 2016. He holds a Ph.D. in Molecular Biology from the University of Liège and is a former FNRS Postdoctoral Researcher of the University of Liège and INSERM in Paris.

IMCYSE Gene Mack

Gene Mack

Chief Financial Officer

Gene Mack joined Imcyse in November 2021 as Chief Financial Officer. He has over 25 years of experience in the life sciences sector, with particular focus on capital markets, business development and corporate finance. Prior to joining Imcyse, Gene was CFO at OncoC4, a privately held biotechnology company that spun out of MSD’s acquisition of OncoImmune. Before that, he has held the CFO role for several development- and commercial-stage biopharmaceutical companies, raising over $150 million in IPO and other equity transactions. Prior to his operational experience, Gene covered the biotechnology and life sciences sector a senior publishing analyst at various investment banks, including Gruntal & Co, Lazard, and HSBC. Gene received his BS in Biochemistry and MBA in Finance from Fordham University.

Andrew Mackie

Chief Business Officer

Andrew Mackie joined Imcyse in July 2020 focusing on Corporate Development and establishing industry partnerships. Prior to joining Imcyse, Andrew has held positions in Business Development, R&D and Investing at Biotech, Pharma and Venture Capital firms including Novartis, Sanofi, and Eli Lilly. Andrew has worked at a number of biotech companies, including Antisoma where he was Head of Clinical Development and Alliance Management and was CBO of Ergomed. Andrew holds a BSc in Biochemistry from Queen’s University in Canada, an LLB (Law) from the University of London and an MBA from the London Business School.

IMCYSE Antoon Van Oossterhout

Antoon Van Oosterhout, Ph.D 

Chief Scientific Officer

Antoon Van Oosterhout was appointed Vice President of Research and Development and Chief Scientific Officer of Imcyse in January 2020. He has more than 25 years’ experience in research and development in the fields of immunology and asthma. Antoon is a guest professor at the University Medical Center of Groningen for Immunology of Lung Diseases. Prior to joining Imcyse, he served as Vice President of GSK’s Allergic Inflammation Discovery Performance Unit until April 2019. Antoon holds a Ph.D. in Immunology from the University of Utrecht.

IMCYSE Jean Van Rampelbergh

Jean Van Rampelbergh, Ph.D

Chief Clinical Development Officer

Jean Van Rampelbergh was appointed Vice President Clinical and Regulatory in January 2020 after joining Imcyse in March 2016 as Clinical Director and Independent Adviser. He has over 20 years’ experience in clinical trials management. Former Clinical Director at Sanofi Belgium, he held different positions at Janssen Research Foundation, Inserm, Organon, Sanofi-Aventis and Novellas Healthcare. Jean, holds a Ph.D. in Biomedical Sciences from the Faculty of Medicine, University of Brussels (ULB).

IMCYSE Luc Vander Elst

Luc Vander Elst

TecOps Director

Luc Vander Elst has been part of Imcyse’s management team since its inception and worked for over 20 years on the Company’s technology. He is in charge of research and development management, ImotopeTM design and development as well as preclinical research and development. Luc holds an Engineering degree in Chemistry option Biochemistry and an M.Sc. in Immunology and genetic from the Catholic University of Leuven (KUL), and worked as a researcher for KUL in the Immunology Group of the Center for Vascular and Molecular Biology which is at the origin of Imcyse’s technology.



Avenue Pré-Aily 14
4031 Liège (Angleur)

Phone : +32 (0)4 325 1100